Physician profile
David J Warrow
NPI 1275776049
$78,339.56
in general payments reported to CMS, 2019-2025
37 companies · $2,110 in 2025
The $2,110 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $329 · 2021: $698 · 2022: $25K · 2023: $33K · 2024: $17K · 2025: $2,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Travel and Lodging: $10K · Food and Beverage: $7,715 · Honoraria: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,455.00 |
| Travel and Lodging | $10,336.88 |
| Food and Beverage | $7,715.16 |
| Honoraria | $1,390.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $48,905.00 | 2022-2023 | Hillrom - Retinavue 700 Imager, Hillrom - Retinavue Network |
| Samsung Bioepis Co., Ltd. | $13,421.42 | 2024 | |
| Bausch & Lomb Americas INC. | $3,239.58 | 2022-2025 | Xipere, Miebo, Visudyne |
| Alimera Sciences, INC. | $1,862.15 | 2019-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $1,431.13 | 2019-2025 | Vabysmo |
| Mallinckrodt Hospital Products INC. | $1,301.80 | 2021-2025 | Acthar |
| Apellis Pharmaceuticals, INC. | $1,254.68 | 2022-2025 | Syfovre |
| Biogen, INC. | $1,176.08 | 2022-2025 | Byooviz |
| Harrow Eye, LLC | $876.57 | 2024-2025 | Iheezo, Triesence, Vevye |
| Abbvie INC. | $809.98 | 2022-2025 | Ozurdex, Vuity |
| Allergan, INC. | $720.20 | 2019-2022 | |
| Eyepoint US, INC. | $431.28 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $370.54 | 2021-2025 | Eylea Hd, Eylea |
| Sun Pharmaceutical Industries INC. | $279.67 | 2024-2025 | |
| Coherus Oncology, INC. | $264.27 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $222.14 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $210.47 | 2019-2020 | |
| Astellas Pharma US INC | $200.71 | 2023 | |
| Neurotech Pharmaceuticals, INC. | $164.16 | 2025 | |
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Regeneron Pharmaceuticals, INC. | $146.21 | 2023 | Eylea |
| Kala Pharmaceuticals, INC. | $144.27 | 2021-2022 | |
| Oyster Point Pharma, INC. | $142.53 | 2022-2023 | Tyrvaya |
| Ani Pharmaceuticals, INC. | $136.76 | 2024-2025 | Iluvien, Yutiq, Purified Cortrophin Gel |
| Astellas Pharma Global Development | $127.07 | 2025 | Izervay |
| Mallinckrodt Enterprises LLC | $112.83 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $106.23 | 2022 | |
| Sandoz INC. | $63.77 | 2024 | Cimerli |
| Thrombogenics, INC. | $33.70 | 2019 | |
| Spark Therapeutics, INC. | $18.59 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.77 | 2020 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Warrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.